Liver Image Guided High Dose Radiation Therapy for the Treatment of Colorectal Liver Metastases
TROG13.02: A phase II single arm trial of stereotactic image guided radiotherapy for colo-rectal liver metastases to determine if it can be performed in a multidisciplinary setting with acceptable toxicity (Liver Image Guided High Dose Radiation Therapy)
Trans Tasman Radiation Oncology Group (TROG)
30 participants
Jul 1, 2017
Interventional
Conditions
Summary
Colo-rectal cancer is increasing in the community and the most common site of spread is to the liver. Isolated liver deposits can be cured by surgery. For patients not fit or suitable for surgery other options need to be investigated. This clinical trial is investigating the use of stereotactic image guided radiotherapy for the treatment of colorectal liver metastases. Who is it for? This study will recruit participants that are aged 18 years or above and have up to 5 medically or surgically inoperable colorectal cancer liver metastases. Study details: All participants in this study will undergo stereotactic radiation therapy. This is a type of external radiation therapy that uses special equipment to more precisely deliver radiation to a tumour. Six radiotherapy sessions will be delivered over 2-3 weeks. Participants will be assessed for 3 years post treatment in order to evaluate treatment safety and disease response.
Eligibility
Inclusion Criteria1
- Patients with up to 5 medically or surgically inoperable colo-rectal cancer liver metastases with a maximum metastasis size of 8cm in whom progression of the liver disease is expected to cause significant morbidity are eligible for the trial
Exclusion Criteria1
- Patients with previous upper abdominal radiotherapy or inadequate liver reserve (<800mL of normal liver) will be excluded from the trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Stereotactic Radiation; Six fractions of radiotherapy delivered with 2-3 fractions per week at least one fraction 24 hours apart per week with risk adjusted dosing based on mean liver dose; 1. 60Gy in 6# delivered over 2-3 weeks for mean liver dose < 13.3Gy 2. 51Gy in 6# delivered over 2-3 weeks for mean liver dose 13.3-15.0Gy 3. 42Gy in 6# delivered over 2-3 weeks for mean liver dose 15.1-17.5Gy
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613001066774